Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 4/2021

01-04-2021 | Care | Original Paper

Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States

Authors: Catherine R. Lesko, Robin M. Nance, Bryan Lau, Anthony T. Fojo, Heidi E. Hutton, Joseph A. C. Delaney, Heidi M. Crane, Karen L. Cropsey, Kenneth H. Mayer, Sonia Napravnik, Elvin Geng, W. Christopher Mathews, Mary E. McCaul, Geetanjali Chander, the CNICS

Published in: AIDS and Behavior | Issue 4/2021

Login to get access

Abstract

We examined HIV viral load non-suppression (\(\ge \) 200 copies/mL) subsequent to person-periods (3–18 months) bookended by two self-reports of alcohol use on a standardized patient reported outcome assessment among adults in routine HIV care. We examined the relative risk (RR) of non-suppression associated with increases and decreases in alcohol use (relative to stable use), stratified by use at the start of the person-period. Increases in drinking from abstinence were associated with higher risk of viral non-suppression (low-risk without binge: RR 1.16, 95% CI 1.03, 1.32; low-risk with binge: RR 1.35, 95% CI 1.11, 1.63; high-risk: RR 1.89, 95% CI 1.16, 3.08). Decreases in drinking from high-risk drinking were weakly, and not statistically significantly associated with lower risk of viral non-suppression. Other changes in alcohol use were not associated with viral load non-suppression. Most changes in alcohol consumption among people using alcohol at baseline were not strongly associated with viral non-suppression.
Literature
1.
Crane HM, McCaul ME, Chander G, Hutton H, Nance RM, Delaney JAC, et al. Prevalence and factors associated with hazardous alcohol use among persons living with HIV across the US in the current era of antiretroviral treatment. AIDS Behav. 2017;21(7):1914–25.PubMedPubMedCentralCrossRef
2.
Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. J Stud Alcohol. 2002;63(2):179–86.PubMedCrossRef
3.
Chander G, Lau B, Moore RD. Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr. 2006;43(4):411–7.PubMedPubMedCentralCrossRef
4.
Marshall BD, Operario D, Bryant KJ, Cook RL, Edelman EJ, Gaither JR, et al. Drinking trajectories among HIV-infected men who have sex with men: a cohort study of United States veterans. Drug Alcohol Depend. 2015;148:69–76.PubMedCrossRef
5.
Neblett RC, Hutton HE, Lau B, McCaul ME, Moore RD, Chander G. Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival. J Womens Health (Larchmt). 2011;20(2):279–86.CrossRef
6.
Barai N, Monroe A, Lesko C, Lau B, Hutton H, Yang C, et al. The association between changes in alcohol use and changes in antiretroviral therapy adherence and viral suppression among women living with HIV. AIDS Behav. 2017;21(7):1836–45.PubMedPubMedCentralCrossRef
7.
Hutton HE, McCaul ME, Chander G, Jenckes MW, Nollen C, Sharp VL, et al. Alcohol use, anal sex, and other risky sexual behaviors among HIV-infected women and men. AIDS Behav. 2013;17(5):1694–704.PubMedCrossRef
8.
Vagenas P, Azar MM, Copenhaver MM, Springer SA, Molina PE, Altice FL. The impact of alcohol use and related disorders on the HIV continuum of care: a systematic review. Curr HIV/AIDS Rep. 2015;12(4):421–36.PubMedPubMedCentralCrossRef
9.
Hahn JA, Cheng DM, Emenyonu NI, Lloyd-Travaglini C, Fatch R, Shade SB, et al. Alcohol use and HIV disease progression in an antiretroviral naive cohort. JAIDS J Acquir Immune Defic Syndr. 2018;77(5):492–501.PubMedCrossRef
10.
Cook R, Zhou Z, Kelso-Chichetto N, Janelle J, Morano J, Somboonwit C, et al. Alcohol consumption patterns and HIV viral suppression among persons receiving HIV care in Florida: an observational study. Addict Sci Clin Pract. 2017;12(1):22.PubMedPubMedCentralCrossRef
11.
Marshall BD, Tate JP, McGinnis KA, Bryant KJ, Cook RL, Edelman EJ, et al. Long-term alcohol use patterns and HIV disease severity. AIDS (London, England). 2017;31(9):1313.CrossRef
12.
Wu ES, Metzger DS, Lynch KG, Douglas SD. Association between alcohol use and HIV viral load. J Acquir Immune Defic Syndr (1999). 2011;56(5):e129.CrossRef
13.
Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: review and meta-analysis. J Acquir Immune Defic Syndr (1999). 2009;52(2):180.CrossRef
14.
Kelso-Chichetto NE, Plankey M, Abraham AG, Ennis N, Chen X, Bolan R, et al. Association between alcohol consumption trajectories and clinical profiles among women and men living with HIV. Am J Drug Alcohol Abuse. 2018;44(1):85–94.PubMedCrossRef
15.
Lesko CR, Tong W, Moore RD, Lau B. Retention, antiretroviral therapy use and viral suppression by history of injection drug use among HIV-infected patients in an urban HIV clinical cohort. AIDS Behav. 2017;21(4):1016–24.PubMedPubMedCentralCrossRef
16.
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844–5.PubMedCrossRef
17.
Yehia BR, Fleishman JA, Metlay JP, Moore RD, Gebo KA. Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA. 2012;308(4):339–42.PubMedPubMedCentralCrossRef
18.
Nance RM, Delaney JC, Simoni JM, Wilson IB, Mayer KH, Whitney BM, et al. HIV viral suppression trends over time among HIV-infected patients receiving care in the United States, 1997 to 2015: a cohort study. Ann Intern Med. 2018;169(6):376–84.PubMedPubMedCentralCrossRef
19.
Williams EC, McGinnis KA, Tate JP, Matson TE, Rubinsky AD, Bobb JF, et al. HIV disease severity is sensitive to temporal changes in alcohol use: a National Study of VA Patients with HIV. J Acquir Immune Defic Syndr. 2019;81:448.PubMedPubMedCentralCrossRef
20.
Williams EC, McGinnis KA, Bobb JF, Rubinsky AD, Lapham GT, Skanderson M, et al. Changes in alcohol use associated with changes in HIV disease severity over time: a national longitudinal study in the Veterans Aging Cohort. Drug Alcohol Depend. 2018;189:21–9.PubMedPubMedCentralCrossRef
21.
Kitahata MM, Rodriguez B, Haubrich R, Boswell S, Mathews WC, Lederman MM, et al. Cohort profile: the centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol. 2008;37(5):948–55.PubMedPubMedCentralCrossRef
22.
Crane HM, Lober W, Webster E, Harrington RD, Crane PK, Davis TE, et al. Routine collection of patient-reported outcomes in an HIV clinic setting: the first 100 patients. Curr HIV Res. 2007;5(1):109–18.PubMedCrossRef
23.
Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. Alcoholism. 2007;31(7):1208–17.PubMedCrossRef
24.
Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. Arch Intern Med. 1998;158(16):1789–95.PubMedCrossRef
25.
Higgins-Biddle JC, Babor TF. A review of the Alcohol Use Disorders Identification Test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions. Am J Drug Alcohol Abuse. 2018;44(6):578–86.PubMedPubMedCentralCrossRef
26.
Humeniuk R, Ali R, Babor TF, Farrell M, Formigoni ML, Jittiwutikarn J, et al. Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction. 2008;103(6):1039–47.PubMedCrossRef
27.
WHO Assist Working Group. The alcohol, smoking and substance involvement screening test (ASSIST): development, reliability and feasibility. Addiction. 2002;97(9):1183–94.CrossRef
28.
Wittkampf KA, Baas KD, van Weert HC, Lucassen P, Schene AH. The psychometric properties of the panic disorder module of the Patient Health Questionnaire (PHQ-PD) in high-risk groups in primary care. J Affect Disord. 2011;130(1–2):260–7.PubMedCrossRef
29.
Kroenke K, Spitzer RL. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann. 2002;32(9):509–15.CrossRef
30.
31.
Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32–6.PubMedCrossRef
32.
Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473–83.PubMedCrossRef
33.
Justice AC, Modur S, Tate JP, Althoff KN, Jacobson LP, Gebo K, et al. Predictive accuracy of the Veterans Aging Cohort Study (VACS) index for mortality with HIV infection: a north American cross cohort analysis. J Acquir Immune Defic Syndr (1999). 2013;62(2):149.CrossRef
34.
Howe CJ, Cole SR, Westreich DJ, Greenland S, Napravnik S, Eron JJ Jr. Splines for trend analysis and continuous confounder control. Epidemiology. 2011;22(6):874–5.PubMedPubMedCentralCrossRef
35.
Hanley JA, Negassa A, Edwardes MD, Forrester JE. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol. 2003;157(4):364–75.PubMedCrossRef
36.
37.
Rubin DB. Multiple imputation after 18+ years. J Am Stat Assoc. 1996;91(434):473–89.CrossRef
38.
White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–99.CrossRefPubMed
39.
40.
Bilal U, McCaul ME, Crane HM, Mathews WC, Mayer KH, Geng E, et al. Predictors of longitudinal trajectories of alcohol consumption in people with HIV. Alcohol Clin Exp Res. 2018;42(3):561–70.PubMedPubMedCentralCrossRef
41.
Marshall BDL, Fairbairn N, Li K, Wood E, Kerr T. Physical violence among a prospective cohort of injection drug users: a gender-focused approach. Drug Alcohol Depend. 2008;97(3):237–46.PubMedPubMedCentralCrossRef
42.
Nolen-Hoeksema S. Gender differences in risk factors and consequences for alcohol use and problems. Clin Psychol Rev. 2004;24(8):981–1010.PubMedCrossRef
43.
Paolillo EW, Gongvatana A, Umlauf A, Letendre SL, Moore DJ. At-risk alcohol use is associated with antiretroviral treatment nonadherence among adults living with HIV/AIDS. Alcoholism. 2017;41(8):1518–25.PubMedCrossRef
44.
Cook RT, Stapleton JT, Ballas ZK, Klinzman D. Effect of a single ethanol exposure on HIV replication in human lymphocytes. J Investig Med. 1997;45(5):265–71.PubMed
45.
Midde NM, Sinha N, Lukka PB, Meibohm B, Kumar S. Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS ONE. 2017;12(2):e0172628.PubMedPubMedCentralCrossRef
46.
Kalichman SC, Grebler T, Amaral CM, McNerney M, White D, Kalichman MO, et al. Viral suppression and antiretroviral medication adherence among alcohol using HIV-positive adults. Int J Behav Med. 2014;21(5):811–20.PubMedPubMedCentralCrossRef
47.
Conen A, Wang Q, Glass TR, Fux CA, Thurnheer MC, Orasch C, et al. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. JAIDS J Acquir Immune Defic Syndr. 2013;64(5):472–8.PubMedCrossRef
48.
Nolan S, Walley AY, Heeren TC, Patts GJ, Ventura AS, Sullivan MM, et al. HIV-infected individuals who use alcohol and other drugs, and virologic suppression. AIDS Care. 2017;29(9):1129–36.PubMedPubMedCentralCrossRef
49.
Matson TE, McGinnis KA, Rubinsky AD, Frost MC, Czarnogorski M, Bryant KJ, et al. Gender and alcohol use: influences on HIV care continuum in a national cohort of patients with HIV. AIDS. 2018;32(15):2247–53.PubMedCrossRef
50.
Palepu A, Horton NJ, Tibbetts N, Meli S, Samet JH. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. Addiction. 2004;99(3):361–8.PubMedCrossRef
51.
Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16(5):767–74.PubMedCrossRef
52.
Lesko CR, Keil AP, Fojo AT, Chander G, Lau B, Moore RD. Recent substance use and probability of unsuppressed HIV viral load among persons on antiretroviral therapy in continuity care. Am J Epidemiol. 2019;188:1830.PubMedPubMedCentralCrossRef
53.
van Smeden M, Lash TL, Groenwold RH. Reflection on modern methods: five myths about measurement error in epidemiological research. Int J Epidemiol. 2019;49:338.PubMedCentralCrossRef
54.
Lucas N, Windsor TD, Caldwell TM, Rodgers B. Psychological distress in non-drinkers: associations with previous heavy drinking and current social relationships. Alcohol Alcohol. 2009;45(1):95–102.PubMedCrossRef
55.
Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr (1999). 2007;46(4):443.CrossRef
56.
Parry CD, Morojele NK, Myers BJ, Kekwaletswe CT, Manda SO, Sorsdahl K, et al. Efficacy of an alcohol-focused intervention for improving adherence to antiretroviral therapy (ART) and HIV treatment outcomes–a randomised controlled trial protocol. BMC Infect Dis. 2014;14(1):500.PubMedPubMedCentralCrossRef
57.
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: results from a double-blind, placebo-controlled trial. JAIDS J Acquir Immune Defic Syndr. 2018;79(1):92–100.PubMedCrossRef
58.
Edelman EJ, Maisto SA, Hansen NB, Cutter CJ, Dziura J, Deng Y, et al. Integrated stepped alcohol treatment for patients with HIV and alcohol use disorder: a randomised controlled trial. Lancet HIV. 2019;6:e509.PubMedPubMedCentralCrossRef
59.
Scott-Sheldon LAJ, Carey KB, Johnson BT, Carey MP, MR Team. Behavioral interventions targeting alcohol use among people living with HIV/AIDS: a systematic review and meta-analysis. AIDS Behav. 2017;21(Suppl 2):126–43.PubMedPubMedCentralCrossRef
60.
Chander G, Hutton HE, Lau B, Xu X, McCaul ME. Brief intervention decreases drinking frequency in HIV-infected, heavy drinking women: results of a randomized controlled trial. J Acquir Immune Defic Syndr. 2015;70(2):137–45.PubMedPubMedCentralCrossRef
61.
Naar-King S, Parsons JT, Murphy DA, Chen X, Harris DR, Belzer ME. Improving health outcomes for youth living with the human immunodeficiency virus: a multisite randomized trial of a motivational intervention targeting multiple risk behaviors. Arch Pediatr Adolesc Med. 2009;163(12):1092–8.PubMedPubMedCentralCrossRef
62.
Naar-King S, Wright K, Parsons JT, Frey M, Templin T, Lam P, et al. Healthy choices: motivational enhancement therapy for health risk behaviors in HIV-positive youth. AIDS Educ Prev. 2006;18(1):1–11.PubMedCrossRef
63.
Sullivan LE, Goulet JL, Justice AC, Fiellin DA. Alcohol consumption and depressive symptoms over time: a longitudinal study of patients with and without HIV infection. Drug Alcohol Depend. 2011;117(2–3):158–63.PubMedPubMedCentralCrossRef
64.
Shuter J. Forgiveness of non-adherence to HIV-1 antiretroviral therapy. J Antimicrob Chemother. 2008;61(4):769–73.PubMedCrossRef
65.
Viswanathan S, Detels R, Mehta SH, Macatangay BJC, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.PubMedPubMedCentralCrossRef
66.
Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE. 2009;4(9):e7196.PubMedPubMedCentralCrossRef
67.
Kobin AB, Sheth NU. Levels of adherence required for virologic suppression among newer antiretroviral medications. Ann Pharmacother. 2011;45(3):372–9.PubMedCrossRef
68.
Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.PubMedCrossRef
69.
Gordon LL, Gharibian D, Chong K, Chun H. Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types. AIDS Patient Care STDs. 2015;29(7):384–8.PubMedCrossRef
70.
Simoni J, Nance R, Delaney J, Wilson I, Aunon F, Safren S, et al., editors. HIV viral load in US clinics over time: trends and predictors from CNICS. Conference on Retroviruses and Opportunistic Infections (2016).
Metadata
Title
Changing Patterns of Alcohol Use and Probability of Unsuppressed Viral Load Among Treated Patients with HIV Engaged in Routine Care in the United States
Authors
Catherine R. Lesko
Robin M. Nance
Bryan Lau
Anthony T. Fojo
Heidi E. Hutton
Joseph A. C. Delaney
Heidi M. Crane
Karen L. Cropsey
Kenneth H. Mayer
Sonia Napravnik
Elvin Geng
W. Christopher Mathews
Mary E. McCaul
Geetanjali Chander
the CNICS
Publication date
01-04-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 4/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-020-03065-z

Other articles of this Issue 4/2021

AIDS and Behavior 4/2021 Go to the issue

Original Paper

Effects of a Home-Based Intervention on HIV Prevention Health Behaviors in Pregnant/Postpartum Kenyan Women: Estimating Moderating Effects of Depressive Symptoms

Original Paper

Transactional Sex, Alcohol Use and Intimate Partner Violence Against Women in the Rakai Region of Uganda

Original Paper

HIV-Risk Behavior Among Adults with Opioid Use Disorder During 12 Months Following Pre-trial Detention: Results from a Randomized Trial of Methadone Treatment

Original Paper

Impact of Medicaid Expansion on PrEP Utilization in the US: 2012–2018

Original Paper

Feasibility and Acceptability of an Adolescent-Friendly Rap Video to Improve Health Literacy Among HIV-Positive Youth in Urban Peru

Original Paper

Pilot Outcomes of Maisha: An HIV Stigma Reduction Intervention Developed for Antenatal Care in Tanzania
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits